Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06263276 in Psoriasis Plaque Test
NCT02193815Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06263276 in Psoriasis vulgaris (PV), sponsored by Pfizer. Primary endpoint: Change From Baseline in Psoriatic Skin Thickness/Echo-Poor Band (EPB) at 12 days. Started Sep 2014; status: completed.
02
Drugs
PF-06263276
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT02193815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193815.